Ignite Creation Date:
2024-05-06 @ 7:07 PM
Last Modification Date:
2024-10-26 @ 3:01 PM
Study NCT ID:
NCT05903989
Status:
COMPLETED
Last Update Posted:
2024-05-10
First Post:
2023-05-25
Brief Title:
Real-World Treatment Patterns and Patient Reported Outcome in COPD REMIND
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Secondary Database Study Using COPD Cohort Study in Japan to Investigate Health Status of COPD Patients With Different Inhaler Treatment
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
REMIND
Brief Summary:
This retrospective observational study aims to report distribution of the proportion of symptomatic Chronic obstructive pulmonary disease COPD patients classified by the COPD Assessment Test CAT managed with single or dual inhaler treatment using the data at cohort entry in the COPD cohort study and treatment change and longitudinal CAT score by each inhaler treatment will also be evaluated using the data during the follow-up period
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None